DETROL
Pronunciation: toel-TER-a-deen (DEE-trol)


What it isMuscarinic antagonist; overactive bladder.
Why this oneIts extended-release capsule causes less dry mouth than the immediate-release tablet, making formulation choice its practical edge.
What limits itAnticholinergic burden persists, so caution in the elderly. CYP2D6 substrate with CYP3A4 backup; QT prolongation.
Animated chart of estimated U.S. prescriptions per year, Overactive bladder meds (1970–2026). Tolterodine enters in 1998 (estimated).
Principal riskAnticholinergic burden
Legacy pregnancy categoryC
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Overactive bladder (urge incontinence, urgency, frequency) | Adults | 2 mg BID | 2 mg BID (may lower to 1 mg BID) | 2 mg BID |
Renal Significantly reduced renal function: 1 mg BID.
Hepatic Significantly reduced hepatic function: 1 mg BID.
Available strengths
Pregnancy Pregnancy Category C; use only if potential benefit justifies risk (animal fetal abnormalities at high doses).
Lactation Undefined.
Generic entry2012
Open Tolterodine in the interactive console ↗
Open Tolterodine in the interactive console ↗